Changes in Access to High Pediatric Readiness Emergency Care in the United States from 2013 to 2021
Abstract
Objective: Many children lack timely access to high pediatric readiness EDs, which are associated with better outcomes. As pediatric expertise centralizes, this pattern may be worsening. We aimed to assess changes in access to high readiness EDs between the 2013 and 2021 editions of the National Pediatric Readiness Project (NPRP) assessments. Study Design: We performed a geospatial analysis of ED responses to the NPRP assessments, linked to Census data. We defined high pediatric readiness EDs as those scoring above the 75th percentile in the 2013 assessment. We defined timely access as living within a 30-minute drive of such an ED. We calculated the proportion of children with timely access nationally, by state, and by hospital referral region, and assessed changes over time. Given potential impacts of the COVID-19 pandemic on staffing, we conducted a secondary analysis excluding staffing-related domains of readiness. Results: Between 2013 and 2021, the proportion of children with timely access to a high readiness ED decreased from 70.2% to 66.7%, representing 2.1 million fewer children. However, many states and regions experienced improvements in access exceeding 10 percentage points. When excluding domains of readiness related to staffing, access to EDs with high equipment- and process-related readiness increased from 75.8% to 79.5%. Conclusions: Pediatric access to high readiness EDs modestly declined over time, but some areas saw meaningful improvements. Excluding…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.